Table 1 Baseline Patient Characteristics (ITT Population)
| Â | Lumiracoxib 100 mg o.d. (n = 755) | Lumiracoxib 100 mg b.i.d. (n = 1,519) | Celecoxib 200 mg o.d. (n = 758) |
|---|---|---|---|
Age (years), mean ± SD | 62.9 ± 10.25 | 62.2 ± 10.02 | 62.7 ± 10.00 |
Females, n (%) | 541 (71.7) | 1081 (71.2) | 531 (70.1) |
BMI (kg/m2), mean ± SD | 29.5 ± 6.41 | 29.7 ± 6.34 | 29.8 ± 6.33 |
Race, n (%) | Â | Â | Â |
   White/Caucasian | 712 (94.3) | 1450 (95.5) | 731 (96.4) |
   Black/African American | 22 (2.9) | 45 (3.0) | 13 (1.7) |
   Hispanic | 10 (1.3) | 8 (0.5) | 11 (1.5) |
   Other†| 11 (1.5) | 16 (1.1) | 3 (0.4) |
Disease duration (years), mean ± SD | 7.9 ± 7.73 | 7.6 ± 7.79 | 7.5 ± 7.62 |
Target joint, n (%) | Â | Â | Â |
   Hip | 58 (7.7) | 122 (8.0) | 59 (7.8) |
   Knee | 376 (49.8) | 743 (48.9) | 350 (46.2) |
   Hand | 159 (21.1) | 301 (19.8) | 166 (21.9) |
   Spine | 162 (21.5) | 353 (23.2) | 183 (24.1) |
OA pain, n (%) | Â | Â | Â |
   Mild | 48 (6.4) | 102 (6.7) | 49 (6.5) |
   Moderate | 363 (48.1) | 704 (46.3) | 346 (45.6) |
   Severe | 343 (45.4) | 712 (46.9) | 361 (47.6) |
   Extreme | 1 (0.1) | 1 (0.1) | 2 (0.3) |
Patient's global assessment of disease activity, n (%) | Â | Â | Â |
   Very good | 2 (0.3) | 8 (0.5) | 4 (0.5) |
   Good | 94 (12.5) | 167 (11.0) | 78 (10.3) |
   Fair | 340 (45.0) | 711 (46.8) | 360 (47.5) |
   Poor | 296 (39.2) | 581 (38.2) | 287 (37.9) |
   Very poor | 23 (3.0) | 51 (3.4) | 29 (3.8) |
Physician's global assessment of disease activity, n (%) | Â | Â | Â |
   Very good | 1 (0.1) | 0 (0.0) | 2 (0.3) |
   Good | 51 (6.8) | 85 (5.6) | 45 (5.9) |
   Fair | 371 (49.1) | 784 (51.6) | 373 (49.2) |
   Poor | 317 (42.0) | 618 (40.7) | 324 (42.7) |
   Very poor | 14 (1.9) | 31 (2.0) | 12 (1.6) |
Short Arthritis assessment Scale (SAS) total score, mean ± SD | 22.4 ± 7.81 | 22.1 ± 7.61 | 22.3 ± 7.86 |